Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Feb 05 2025 09:01

FORT LEE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of...

A Race Against Blindness Announces $2 Million Grant to Support Sight-Saving Clinical Trial

Feb 05 2025 08:15

PHOENIX, Feb. 05, 2025 (GLOBE NEWSWIRE) -- A Race Against Blindness, a nonprofit organization dedicated to funding sight-saving therapies for children, is thrilled to announce a $2.0 million grant was...

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS

Feb 05 2025 08:00

Modified intent-to-treat group demonstrated +22.7 point (p<0.0001) treatment effect in the mean Bayley-III cognitive raw score compared to natural history data (ages 24-60 months)

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Feb 05 2025 08:00

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced...

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Feb 05 2025 08:00

DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing...

E-Star BioTech Announces Dosing of First Patient in Phase 2 Clinical Trials of MANP in Resistant Hypertension

Feb 05 2025 08:00

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney diseases, today announced...

PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Feb 05 2025 08:00

FDA-cleared amended trial design; First site initiation expected Q1 2025

Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

Feb 05 2025 08:00

Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or dose-limiting toxicities

AquaSculpt Publishes Full Natural Ingredients List to Offer Customers Full Transparency and Confidence

Feb 05 2025 08:00

New York, NY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- AquaSculpt, a natural weight loss option that combines a unique formulation with a novel approach known as the Ice Water Hack,...

CAR T-Cell Therapy Market Forecasts to 2035, with Competitor Profiles of Autolus, Bluebird Bio, Carsgen Therapeutics, Cellectis, Noile-Immune Biotech, Shanghai GeneChem, Takara Bio and More

Feb 05 2025 07:45

Close to 1,000 clinical trials related to CAR-T cell therapies have been registered in the past eight years, indicating substantial research activity. At present, over 230 companies are engaged in...

Clinical Trials

Subscribe to global regulatory updates